Baoxiang Technology

Baoxiang Technology is a Shanghai-based biotechnology company dedicated to the development of next-generation targeted protein degradation (TPD) therapies, specifically focusing on molecular glues. The company was founded in 2021 by Dr. Xiaohu Zhang, an industry veteran with a background in global pharmaceutical R&D and a co-founder of Viva Biotech. Baoxiang utilizes a proprietary discovery platform that integrates structural biology, computational modeling, and high-throughput screening to identify small molecules that can recruit E3 ligases to degrade "undruggable" proteins. Their primary therapeutic focus is on oncology, aiming to provide new treatment options for cancers driven by proteins that cannot be targeted by traditional inhibitors. The company has secured significant venture capital funding from prominent investors like Morningside and IDG Capital to advance its early-stage pipeline. Baoxiang represents a key player in the emerging field of molecular glue discovery within the Chinese biotech ecosystem.